Ganaxolone

Drug Profile

Ganaxolone

Alternative Names: CCD-1042; Ganaxalone IV; Ganaxolone IV; gnx

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Infantile spasms; Fragile X syndrome; Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Partial epilepsies
  • Phase II Epilepsy; Fragile X syndrome; Lennox-Gastaut syndrome
  • Phase I Status epilepticus
  • Preclinical Angelman syndrome; Postnatal depression
  • No development reported Post-traumatic stress disorders
  • Discontinued Infantile spasms

Most Recent Events

  • 03 May 2017 Marinus Pharmaceuticals completes a phase II trial in Fragile X syndrome (In children, In adolescents) in USA and Belgium prior to May 2017
  • 28 Apr 2017 Preclinical trials in Postnatal depression in USA, before April 2017
  • 22 Apr 2017 Efficacy and safety data from a phase II trial in Epilepsy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top